Insilico Medicine to present at the 10th Anniversary CHIC Conference
Credit: Insilico Medicine
Thursday, March 21, 2019 – Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery and productive longevity at the 10th Anniversary CHIC Conference in Shanghai, March 26-28.
Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in transforming pharmaceutical industry, making the hunt for new medicines quicker and more effective. The presentation will cover the recent progress in the end-to-end drug discovery pipeline development at Insilico Medicine and recent advances in the generative adversarial networks (GANs) and reinforcement learning (RL) used for generation of novel chemistry, and identification of novel biological targets.
“We are happy to present our latest research at the 10th Anniversary CHIC Conference, which gathers the leading longevity leaders. The topic of AI for Aging research and Productive longevity is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area”, said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The CHIC Conference is the event of the year to meet and learn about upcoming Chinese healthcare companies and industry trends, with senior executives from over 65 of the industry’s most influential companies who will share their insights through keynote presentations and candid panel discussions. The event is held in Shanghai, on March 26-28, 2019.
###
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
For further information, images or interviews, please contact:
Contact: Klug Gehilfe
[email protected]
Website: http://insilico.
Official website of the conference:
http://www.
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
Media Contact
Klug Gehilfe
[email protected]
